Berbamine

A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity

Rongzhen Xu, Qinghua Dong, Yingzi Yu, Xiaoying Zhao, Xiaoxian Gan, Dong Wu, Qinghua Lu, Xiaohua Xu, Xiao Fang Yu

Research output: Contribution to journalArticle

Abstract

Gleevec, which is an inhibitor of the bcr/abl tyrosine kinase, has been a remarkable success for the treatment of chronic myelogenous leukemia (CML). However, a significant proportion of patients chronically treated with Gleevec develop resistance. Here we describe the activity of a natural small molecular compound, berbamine from plant Berberis amurensis that can selectively induce cell death of both Gleevec-sensitive and -resistant Ph+ CML cells. The IC50 values of berbamine were 8.80 μg/ml in Gleevec-sensitive Ph+ CML cells, 11.34 μg/ml in Gleevec-resistant Ph+ CML cells, and 54.40 μg/ml in Ph- KG-1 cells, respectively. Similarly, berbamine was also found to display a selective anti-proliferative activity of primary leukemia cells from CML patients, and its IC50 values were 4.20-10.50 μg/ml in primary CML cells, and 185.20 μg/ml in normal bone marrow cells, respectively. More importantly, our studies demonstrate that berbamine down-regulates p210 bcr/abl oncoprotein level, and induces apoptosis of bcr/abl+ cells through caspase-3-dependent pathway. These data suggest that berbamine might be a novel bcr/abl inhibitor with potent anti-leukemia activity.

Original languageEnglish (US)
Pages (from-to)17-23
Number of pages7
JournalLeukemia Research
Volume30
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

abl Genes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Inhibitory Concentration 50
Berberis
bcr-abl Fusion Proteins
Oncogene Proteins
berbamine
Caspase 3
Bone Marrow Cells
Cell Death
Down-Regulation
Imatinib Mesylate
Apoptosis

Keywords

  • Apoptosis
  • Bcr/abl
  • Berbamine
  • Caspase-3
  • Chronic myeloid leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Berbamine : A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. / Xu, Rongzhen; Dong, Qinghua; Yu, Yingzi; Zhao, Xiaoying; Gan, Xiaoxian; Wu, Dong; Lu, Qinghua; Xu, Xiaohua; Yu, Xiao Fang.

In: Leukemia Research, Vol. 30, No. 1, 01.2006, p. 17-23.

Research output: Contribution to journalArticle

Xu, R, Dong, Q, Yu, Y, Zhao, X, Gan, X, Wu, D, Lu, Q, Xu, X & Yu, XF 2006, 'Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity', Leukemia Research, vol. 30, no. 1, pp. 17-23. https://doi.org/10.1016/j.leukres.2005.05.023
Xu, Rongzhen ; Dong, Qinghua ; Yu, Yingzi ; Zhao, Xiaoying ; Gan, Xiaoxian ; Wu, Dong ; Lu, Qinghua ; Xu, Xiaohua ; Yu, Xiao Fang. / Berbamine : A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. In: Leukemia Research. 2006 ; Vol. 30, No. 1. pp. 17-23.
@article{a0153ef9aa924fa6af1099205c44f3d7,
title = "Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity",
abstract = "Gleevec, which is an inhibitor of the bcr/abl tyrosine kinase, has been a remarkable success for the treatment of chronic myelogenous leukemia (CML). However, a significant proportion of patients chronically treated with Gleevec develop resistance. Here we describe the activity of a natural small molecular compound, berbamine from plant Berberis amurensis that can selectively induce cell death of both Gleevec-sensitive and -resistant Ph+ CML cells. The IC50 values of berbamine were 8.80 μg/ml in Gleevec-sensitive Ph+ CML cells, 11.34 μg/ml in Gleevec-resistant Ph+ CML cells, and 54.40 μg/ml in Ph- KG-1 cells, respectively. Similarly, berbamine was also found to display a selective anti-proliferative activity of primary leukemia cells from CML patients, and its IC50 values were 4.20-10.50 μg/ml in primary CML cells, and 185.20 μg/ml in normal bone marrow cells, respectively. More importantly, our studies demonstrate that berbamine down-regulates p210 bcr/abl oncoprotein level, and induces apoptosis of bcr/abl+ cells through caspase-3-dependent pathway. These data suggest that berbamine might be a novel bcr/abl inhibitor with potent anti-leukemia activity.",
keywords = "Apoptosis, Bcr/abl, Berbamine, Caspase-3, Chronic myeloid leukemia",
author = "Rongzhen Xu and Qinghua Dong and Yingzi Yu and Xiaoying Zhao and Xiaoxian Gan and Dong Wu and Qinghua Lu and Xiaohua Xu and Yu, {Xiao Fang}",
year = "2006",
month = "1",
doi = "10.1016/j.leukres.2005.05.023",
language = "English (US)",
volume = "30",
pages = "17--23",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Berbamine

T2 - A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity

AU - Xu, Rongzhen

AU - Dong, Qinghua

AU - Yu, Yingzi

AU - Zhao, Xiaoying

AU - Gan, Xiaoxian

AU - Wu, Dong

AU - Lu, Qinghua

AU - Xu, Xiaohua

AU - Yu, Xiao Fang

PY - 2006/1

Y1 - 2006/1

N2 - Gleevec, which is an inhibitor of the bcr/abl tyrosine kinase, has been a remarkable success for the treatment of chronic myelogenous leukemia (CML). However, a significant proportion of patients chronically treated with Gleevec develop resistance. Here we describe the activity of a natural small molecular compound, berbamine from plant Berberis amurensis that can selectively induce cell death of both Gleevec-sensitive and -resistant Ph+ CML cells. The IC50 values of berbamine were 8.80 μg/ml in Gleevec-sensitive Ph+ CML cells, 11.34 μg/ml in Gleevec-resistant Ph+ CML cells, and 54.40 μg/ml in Ph- KG-1 cells, respectively. Similarly, berbamine was also found to display a selective anti-proliferative activity of primary leukemia cells from CML patients, and its IC50 values were 4.20-10.50 μg/ml in primary CML cells, and 185.20 μg/ml in normal bone marrow cells, respectively. More importantly, our studies demonstrate that berbamine down-regulates p210 bcr/abl oncoprotein level, and induces apoptosis of bcr/abl+ cells through caspase-3-dependent pathway. These data suggest that berbamine might be a novel bcr/abl inhibitor with potent anti-leukemia activity.

AB - Gleevec, which is an inhibitor of the bcr/abl tyrosine kinase, has been a remarkable success for the treatment of chronic myelogenous leukemia (CML). However, a significant proportion of patients chronically treated with Gleevec develop resistance. Here we describe the activity of a natural small molecular compound, berbamine from plant Berberis amurensis that can selectively induce cell death of both Gleevec-sensitive and -resistant Ph+ CML cells. The IC50 values of berbamine were 8.80 μg/ml in Gleevec-sensitive Ph+ CML cells, 11.34 μg/ml in Gleevec-resistant Ph+ CML cells, and 54.40 μg/ml in Ph- KG-1 cells, respectively. Similarly, berbamine was also found to display a selective anti-proliferative activity of primary leukemia cells from CML patients, and its IC50 values were 4.20-10.50 μg/ml in primary CML cells, and 185.20 μg/ml in normal bone marrow cells, respectively. More importantly, our studies demonstrate that berbamine down-regulates p210 bcr/abl oncoprotein level, and induces apoptosis of bcr/abl+ cells through caspase-3-dependent pathway. These data suggest that berbamine might be a novel bcr/abl inhibitor with potent anti-leukemia activity.

KW - Apoptosis

KW - Bcr/abl

KW - Berbamine

KW - Caspase-3

KW - Chronic myeloid leukemia

UR - http://www.scopus.com/inward/record.url?scp=27844611479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844611479&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.05.023

DO - 10.1016/j.leukres.2005.05.023

M3 - Article

VL - 30

SP - 17

EP - 23

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -